Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
50%
Ph phase_2
1
25%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
N/A2 (50.0%)

Trials by Status

not_yet_recruiting125%
recruiting125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
not_yet_recruitingnot_applicable

Carpal Tunnel Release Efficacy Trial

NCT06934187
recruitingnot_applicable

Trial Comparing Treatment Strategies in Triangular Fibrocartilage Complex Ruptures

NCT04576169
completedphase_3

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face

NCT01720407
completedphase_2

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00876863

Clinical Trials (4)

Showing 4 of 4 trials
NCT06934187Not Applicable

Carpal Tunnel Release Efficacy Trial

Not Yet Recruiting
NCT04576169Not Applicable

Trial Comparing Treatment Strategies in Triangular Fibrocartilage Complex Ruptures

Recruiting
NCT01720407Phase 3

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face

Completed
NCT00876863Phase 2

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4